STOCK TITAN

Edwards Lifesciences (EW) Stock Price, News & Analysis

EW NYSE
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
1 252 sessions, November 14, 2025 to November 16, 2026
Largest daily move
+5.6% close of April 24, 2026
1-year change
+24.1% closing prices, November 14, 2025 to November 16, 2026
1-month change
+23.7% closing prices, October 16, 2026 to November 16, 2026

Company Description

Edwards Lifesciences Corporation (NYSE: EW) is a medical technology company focused on structural heart disease. Classified under surgical appliance and supplies manufacturing, the company is described in its public materials as a global structural heart innovation company driven by a passion to improve patient lives. Its work centers on developing and commercializing heart valve and related therapies for patients with advanced stages of structural heart disease.

According to company disclosures and press releases, Edwards Lifesciences focuses on therapies for aortic stenosis (AS), mitral regurgitation (MR), tricuspid regurgitation (TR), pulmonic disease, aortic regurgitation (AR) and structural heart failure. The company highlights a long history in heart valve innovation, referencing more than 65 years of leadership and valve expertise in its communications. Edwards Lifesciences’ common stock trades on the New York Stock Exchange under the symbol EW.

Core structural heart focus

Edwards Lifesciences describes itself as a structural heart innovation company that develops technologies and evidence to transform care for patients with valvular and related heart disease. Its communications emphasize a portfolio of transcatheter and surgical therapies addressing aortic, mitral, tricuspid and pulmonic valves, as well as emerging areas such as structural heart failure and transcatheter aortic valve replacement for aortic regurgitation (TAVR‑AR).

The company’s transcatheter aortic valve replacement (TAVR) platform, branded SAPIEN, is repeatedly cited in clinical and investor materials. Edwards states that SAPIEN has become a global benchmark for TAVR and notes that it is the most studied valve platform, with more than 15 years of clinical trials, multiple publications in major medical journals and a large number of patients treated worldwide. Data from the PARTNER trial series, including long‑term follow‑up, are used by the company to support the durability and performance of the SAPIEN 3 valve compared with surgical aortic valve replacement.

Transcatheter mitral and tricuspid therapies (TMTT)

In its public updates, Edwards Lifesciences describes a transcatheter mitral and tricuspid therapies (TMTT) portfolio that includes repair and replacement technologies. Named systems in company news releases include the PASCAL mitral valve repair system, the EVOQUE tricuspid valve replacement system and the SAPIEN M3 transcatheter mitral valve replacement (TMVR) system. The company reports that these therapies are intended for patients with complex mitral and tricuspid disease, many of whom have limited or no other treatment options.

Edwards has highlighted pivotal clinical data such as the ENCIRCLE trial for SAPIEN M3 and registry data for the EVOQUE tricuspid valve. The company states that these data demonstrate high rates of regurgitation reduction, safety outcomes and improvements in symptoms and quality of life in patient populations deemed unsuitable for other interventions. Edwards also notes that the SAPIEN M3 system has received regulatory approvals in certain markets and that its portfolio of transcatheter mitral and tricuspid therapies is expanding with next‑generation systems and additional indications, as described in its investor conference materials.

Surgical heart valve and cardiac surgery portfolio

Alongside transcatheter therapies, Edwards Lifesciences communicates an ongoing focus on surgical heart valve therapies. The company refers to its RESILIA tissue technology and associated platforms such as INSPIRIS, MITRIS and KONECT in its investor presentations and earnings releases. It states that these surgical innovations are intended to address critical unmet needs in cardiac surgery and to support patients best treated with surgical procedures, including complex and concomitant operations.

Edwards also references plans for additional surgical products, such as TRIFORMIS, described in company communications as a surgical valve designed for the tricuspid position. These references illustrate the company’s strategy of maintaining a presence in both transcatheter and surgical segments of structural heart therapy.

Emerging areas: structural heart failure and AR

In its investor conference materials, Edwards Lifesciences identifies structural heart failure and transcatheter treatment of aortic regurgitation as emerging therapeutic areas. The company describes plans to develop implantable pressure sensor–guided management solutions for heart failure and to advance TAVR‑AR as a new frontier in aortic valve disease treatment. It characterizes aortic regurgitation as a deadly, progressive disease with limited treatment options and presents itself as aiming to lead AR therapy through novel transcatheter valve technologies and clinical trials.

Edwards has also reported that it sought to acquire JenaValve Technology, a company associated with AR therapy, but an injunction granted to the U.S. Federal Trade Commission blocked the proposed acquisition. In an 8‑K filing and related press release, Edwards stated that, as a result, it would not acquire JenaValve and that it would continue to advance its own AR therapy programs, including the SOJOURN transcatheter AR valve and the JOURNEY pivotal trial.

Clinical evidence and partnerships

Across multiple press releases and conference summaries, Edwards Lifesciences emphasizes the role of clinical evidence in its business. The company highlights late‑breaking trial presentations at major cardiology meetings, including Transcatheter Cardiovascular Therapeutics (TCT), and publications in journals such as The New England Journal of Medicine and The Lancet. It points to long‑term outcomes data from the PARTNER trial series, the ENCIRCLE TMVR trial, and real‑world registries for EVOQUE as examples of evidence supporting its therapies.

Edwards also describes partnerships with clinicians, health systems and professional organizations. For example, it has announced founding sponsorship of the American Heart Association’s Heart Valve Initiative, which focuses on improving care and outcomes for patients with heart valve disease through guideline‑based care, data collection, certification programs and education. The company portrays these collaborations as aligned with its patient‑focused culture.

Investor communications and capital markets activity

Edwards Lifesciences regularly issues earnings releases and hosts conference calls to discuss financial results and outlook. In its 8‑K filings, the company reports quarterly sales by product group, adjusted earnings per share guidance and other financial metrics, while noting that certain figures are presented on a non‑GAAP basis. It also discloses activities such as accelerated share repurchase agreements and share repurchase authorizations approved by its board of directors.

The company participates in major healthcare investment conferences, such as the J.P. Morgan Healthcare Conference, where it presents its strategy and financial guidance. In these forums, Edwards describes its structural heart portfolio, growth expectations for TAVR, TMTT and surgical product groups, and its intention to continue investing in research and development for structural heart therapies.

Headquarters and corporate structure

Edwards Lifesciences Corporation is incorporated in Delaware and lists its principal executive offices in Irvine, California, in its SEC filings. The company’s common stock, with a par value of $1.00 per share, is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on the New York Stock Exchange under the symbol EW.

Position within the medical device industry

Within the broader medical device and manufacturing sector, Edwards Lifesciences is categorized under surgical appliance and supplies manufacturing. Its public statements consistently describe the company as a global structural heart innovation company with therapies across transcatheter and surgical modalities. The firm’s focus on structural heart disease, heart valve therapies and related technologies distinguishes it within this industry classification.

Stock Performance

$107.11
-0.04%
-0.04
Last updated: November 16, 2026 at 16:00
+24.1%
Performance 1 year
$61.6B

Edwards Lifesciences (EW) closed at $107.11 on November 16, 2026. Over the past 12 months, the price has gained 24.1%.

See what a $1,000 investment in EW would be worth today

Average down calculator for EW

EW Metrics & Rankings

Price returns through November 16, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
110,085
Shares Sold
11
Transactions
Most Recent Transaction
Lippis Daniel J. (CVP, TAVR) sold 619 shares @ $104.25 on November 10, 2026

Insider selling at Edwards Lifesciences over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Edwards Lifesciences generated $6.1B in revenue in FY2025, retaining a 78.0% gross margin, operating income reached $1.3B (20.8% operating margin), and net income was $1.1B, reflecting a 17.7% net profit margin. Diluted earnings per share stood at $1.83. The company generated $1.6B in operating cash flow. The current ratio was 3.72, measuring current assets divided by current liabilities.

$6.1B
Revenue (FY2025)
$1.1B
Net Income (FY2025)
$1.6B
Operating Cash Flow

Upcoming Events

DEC
2026
December 2026 Earnings

Investor Conference

Edwards will present 2027 and longer-term financial guidance at its investor conference in December 2026; webcast details TBA.
YEAR
2030
2030 Corporate

Every Heartbeat Matters deadline

Target to help 2M additional patients globally under Every Heartbeat Matters by end of 2030

Edwards Lifesciences has 2 upcoming scheduled events. The next event, "Investor Conference", is expected in December 2026. 1 of them is an earnings release or call. Investors can track these dates to stay informed about potential catalysts that may affect the EW stock price.

Short Interest History

Last 12 Months

Short interest in Edwards Lifesciences (EW) currently stands at 9.4 million shares, up 0.5% from the previous reporting period, representing 1.6% of the float. Since November 2025, short interest has increased by 34.4%.

Days to Cover History

Last 12 Months

Days to cover for Edwards Lifesciences (EW) currently stands at 2.8 days, up 13.8% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 53.8%. Across the settlements charted above, it has ranged from 1.3 to 3.2 days.

EW Company Profile & Sector Positioning

Edwards Lifesciences (EW) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the NYSE.

Investors comparing EW often look at related companies in the same sector, including Boston Scientific Corporation (BSX), GE HealthCare Technologies Inc. (GEHC), Stryker Corporation (SYK), DexCom, Inc. (DXCM), and Medtronic plc (MDT). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate EW's relative position within its industry.

Frequently Asked Questions

The current stock price of Edwards Lifesciences (EW) is $107.11 as of November 16, 2026.

The market cap of Edwards Lifesciences (EW) is approximately $61.6B. Learn more about what market capitalization means .

The FY2025 revenue of Edwards Lifesciences (EW) is $6.1B, from its most recent completed fiscal year.

The FY2025 net income of Edwards Lifesciences (EW) is $1.1B, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Edwards Lifesciences (EW) is $1.83 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Edwards Lifesciences (EW) is $1.6B for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Edwards Lifesciences (EW) is 17.7% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Edwards Lifesciences (EW) is 20.8% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Edwards Lifesciences (EW) is 78.0% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Edwards Lifesciences (EW), current assets divided by current liabilities, was 3.72 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Edwards Lifesciences (EW) is $4.7B for FY2025, its most recent completed fiscal year.

The operating income of Edwards Lifesciences (EW) is $1.3B for FY2025, its most recent completed fiscal year. Learn about operating income.